Recording of non-operating expenses and extraordinary losses
Carna Biosciences,Inc. (filing company; consolidated financial statements)
Interest expenses mainly comprised the amortization of issuance discounts arising at the issuance of convertible bonds with stock acquisition rights and bonds, as well as interest on convertible bonds with stock acquisition rights. The impairment loss resulted from reducing assets for which indications of impairment had been identified to their recoverable amounts.
During the second-quarter consolidated accounting period, the Company recorded ¥21,033 thousand in interest expenses (non-operating expenses) and ¥9,344 thousand in impairment losses (extraordinary loss). For the cumulative interim consolidated accounting period, interest expenses totaled ¥34,219 thousand and impairment losses totaled ¥12,350 thousand.
Second-quarter consolidated accounting period of the fiscal year ending December 2026 (1 April 2026 to 30 June 2026). The interim consolidated accounting period runs from 1 January 2026 to 30 June 2026.
The above non-operating expenses and extraordinary losses have been reflected in the “Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 2026 under Japanese GAAP,” released today.
| Item | Details |
|---|---|
| Event name | Recording of non-operating expenses and extraordinary losses |
| Date of occurrence | 1 April 2026 to 30 June 2026 (second-quarter consolidated accounting period; specific accounting date: Not disclosed) |
| Subject Entity | Carna Biosciences,Inc. (filing company; consolidated financial statements) |
| Cause | Interest expenses mainly comprised the amortization of issuance discounts arising at the issuance of convertible bonds with stock acquisition rights and bonds, as well as interest on convertible bonds with stock acquisition rights. The impairment loss resulted from reducing assets for which indications of impairment had been identified to their recoverable amounts. |
| Amount of Impact on Business Performance | During the second-quarter consolidated accounting period, the Company recorded ¥21,033 thousand in interest expenses (non-operating expenses) and ¥9,344 thousand in impairment losses (extraordinary loss). For the cumulative interim consolidated accounting period, interest expenses totaled ¥34,219 thousand and impairment losses totaled ¥12,350 thousand. |
| Accounting period in which recognized | Second-quarter consolidated accounting period of the fiscal year ending December 2026 (1 April 2026 to 30 June 2026). The interim consolidated accounting period runs from 1 January 2026 to 30 June 2026. |
| Outlook | The above non-operating expenses and extraordinary losses have been reflected in the “Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 2026 under Japanese GAAP,” released today. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Interest expenses mainly comprised the amortization of issuance discounts arising at the issuance of convertible bonds with stock acquisition rights and bonds, as well as interest on convertible bonds with stock acquisition rights. The impairment loss resulted from reducing assets for which indications of impairment had been identified to their recoverable amounts.